Innovations in glp-1 receptor agonists: Immune therapy applications.

Nadem Ahmed*

Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Saudi Arabia

Introduction

In recent years, the development of GLP-1 receptor agonists (GLP-1 RAs) has emerged as one of the most innovative advancements in the treatment of metabolic diseases such as type 2 diabetes (T2D) and obesity. However, growing evidence suggests that these molecules could have broader applications, including in immune therapy for autoimmune diseases and cancer. This article explores the innovations surrounding GLP-1 receptor agonists and their potential applications in immune therapy [1].

Glucagon-like peptide-1 (GLP-1) is an endogenous hormone that plays a key role in regulating glucose metabolism by enhancing insulin secretion, inhibiting glucagon release, and slowing gastric emptying. These functions contribute to lowering blood sugar levels and promoting satiety. GLP-1 receptor agonists are synthetic compounds designed to mimic the effects of GLP-1 by binding to its receptor (GLP-1R) and activating its downstream signaling pathways [2].

Inflammation is a core feature of many autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease (IBD). GLP-1 receptor agonists have been shown to exert anti-inflammatory effects in preclinical studies. These effects are mediated through the modulation of immune cell function, particularly T cells and macrophages, which play critical roles in inflammatory responses [3].

For example, in models of colitis (a form of IBD), GLP-1 receptor agonists have demonstrated the ability to reduce the expression of pro-inflammatory cytokines and inhibit the infiltration of immune cells into inflamed tissues. Similarly, in autoimmune models of rheumatoid arthritis, GLP-1 RAs have been reported to reduce joint inflammation and prevent tissue damage [4].

This anti-inflammatory potential has prompted researchers to investigate GLP-1 receptor agonists as adjuncts to conventional immunosuppressive therapies for autoimmune conditions. By targeting both metabolic and immune pathways, these therapies could offer dual benefits, improving both metabolic control and reducing inflammation [5].

GLP-1 receptor activation can influence the behavior of various immune cells, including dendritic cells, T cells, and macrophages. Studies suggest that GLP-1 receptor agonists may enhance the regulatory functions of T cells, particularly regulatory T cells (Tregs), which are crucial for maintaining immune tolerance and preventing autoimmune responses.In addition to modulating T cell activity, GLP-1 receptor agonists may impact macrophage polarization. Macrophages can adopt different phenotypes depending on the inflammatory milieu. Research has shown that GLP-1 receptor agonists may skew macrophage differentiation toward an anti-inflammatory (M2) phenotype, which could help resolve chronic inflammation [6].

These immune-modulating effects open the door to the use of GLP-1 RAs in diseases where immune dysregulation plays a central role, such as in autoimmune disorders and graft-versus-host disease (GVHD), where immune cells attack the body's own tissues [7].

Recent advancements in cancer immunotherapy have focused on harnessing the immune system to target and eliminate cancer cells. While immune checkpoint inhibitors such as PD-1/PD-L1 blockers have shown promise in treating various cancers, their effectiveness is limited in some cases, and they can lead to significant side effects [8].

Emerging research suggests that GLP-1 receptor agonists might also play a role in enhancing anti-tumor immunity. GLP-1 receptor activation has been shown to enhance the recruitment and activation of immune cells such as T cells and natural killer (NK) cells, which are critical for targeting tumor cells. Additionally, some studies have suggested that GLP-1 receptor agonists may increase the expression of immune checkpoint molecules in the tumor microenvironment, potentially enhancing the efficacy of existing immunotherapies [9].

Although much of the research into GLP-1 receptor agonists in immune therapy is still in preclinical stages, there have been several clinical trials investigating their effects in immune-related diseases. For instance, studies are underway to assess the safety and efficacy of GLP-1 RAs in combination with traditional immunosuppressive therapies for rheumatoid arthritis and multiple sclerosis.In the oncology field, early-phase trials are exploring the use of GLP-1 receptor agonists alongside immune checkpoint inhibitors to enhance tumor immunity and improve patient response rates. The potential for these agents to complement existing immunotherapies is an exciting avenue of research that may lead to new, more effective treatment options for cancer patients [10].

***Correspondence to : Nadem Ahmed, **Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Saudi Arabia. E-mail**: ndm@ahmd

***Received:** 30-Aug-2024, Manuscript No. AADY-25-158380; **Editor assigned:** 02- Sep -2024, PreQC No. AADY-25-158380 (PQ); **Reviewed:** 11- Sep -2024, QC No. AADY-25-168380;**Revised:** 16-Sep-2024, Manuscript No. AADY-25-158380; **Published:** 25- Sep -2024, DOI: 10.36841/aady-8.5.226*

***Citation:** Ahmed N: Innovations in glp-1 receptor agonists: Immune therapy applications. J Diabetol. 2024;8(5):226*

Conclusion

GLP-1 receptor agonists have revolutionized the treatment of metabolic diseases, but their therapeutic potential extends far beyond the regulation of blood sugar and weight loss. As immunomodulatory agents, they hold promise in the treatment of autoimmune diseases, inflammation, and even cancer. With ongoing research into their immune-modulating properties, GLP-1 receptor agonists could soon play a pivotal role in immune therapies, offering novel, dual-action treatments that address both metabolic and immune-related disorders.

References

1. Hartman ZC, Appledorn DM, Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus research. 2008 Mar 1;132(1-2):1-4.
2. Chang JH, Jiang Y, Pillarisetty VG. Role of immune cells in pancreatic cancer from bench to clinical application: an updated review. Medicine. 2016 Dec 1;95(49):e5541.
3. Look M, Bandyopadhyay A, Blum JS, Fahmy TM. Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Advanced drug delivery reviews. 2010 Mar 18;62(4-5):378-93.
4. Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nature immunology. 2013 Dec;14(12):1212-8.
5. Soetaert F, Korangath P, Serantes D, Fiering S, Ivkov R. Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies. Advanced drug delivery reviews. 2020 Jan 1;163:65-83.
6. Jiang GM, Tan Y, Wang H, Peng L, Chen HT, Meng XJ, Li LL, Liu Y, Li WF, Shan H. The relationship between autophagy and the immune system and its applications for tumor immunotherapy. Molecular cancer. 2019 Dec;18:1-22.
7. Sun Q, Hong Z, Zhang C, Wang L, Han Z, Ma D. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal transduction and targeted therapy. 2023 Aug 28;8(1):320.
8. Nidetz NF, McGee MC, Longping VT, Li C, Cong L, Li Y, Huang W. Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery. Pharmacology & therapeutics. 2020 Mar 1;207:107453.
9. Stevenson HC, Green I, Hamilton JM, Calabro BA, Parkinson DR. Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer. Journal of clinical oncology. 1991 Nov;9(11):2052-66.
10. Sushnitha M, Evangelopoulos M, Tasciotti E, Taraballi F. Cell membrane-based biomimetic nanoparticles and the immune system: immunomodulatory interactions to therapeutic applications. Frontiers in bioengineering and biotechnology. 2020 Jun 17;8:627.

Citation: *Ahmed N: Innovations in glp-1 receptor agonists: Immune therapy applications. J Diabetol. 2024;8(5):226*